Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Ciltacabtagene autoleucel benefit for lenalidomide-refractory FHR multiple myeloma

ASCO 2024

31 May - 4 Jun 2024

Published: 2 Jun 2024

Views: 32

Rating:

Save

Dr Luciano Costa - University Of Alabama At Birmingham, Birmingham, USA

Dr Luciano Costa speaks to ecancer at ASCO 2024 about results from the subgroup analysis from the CARTITUDE-4 study, which evaluated ciltacabtagene autoleucel vs standard of care in patients with functional high-risk multiple myeloma.

He explians that in the initial analysis, a single ciltacabtagene autoleucel infusion significantly improved progression-free survival vs established standard of care.

Dr Costa reports that in patients with len-refractory FHR MM after 1 prior line of treatment, ciltacabtagene autoleucel improved outcomes vs standard of care.

Related Videos

EHA 2024: Multiple myeloma roundup

Dr Claudio Cerchione - IRCCS, Meldola, Italy

EHA 2024: Multiple myeloma roundup ( Dr Claudio Cerchione - IRCCS, Meldola, Italy )

Immune therapy with belantamab mafodotin and elotuzumab shows encouraging...

Dr Natalia Neparidze - Yale School of Medicine, New Haven, USA

CAR-T, bispecifics or ADCs in late-stage RRMM

Dr Elena Zamagni - University of Bologna, Bologna, Italy

CAR-T, bispecifics or ADCs in late-stage RRMM ( Dr Elena Zamagni - University of Bologna, Bologna, Italy )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

Efficacy and safety of belantamab mafodotin vs pomalidomide plus dexamethasone...

Prof Meletios Dimopoulos - National and Kapodistrian University of Athens...

$Efficacy and safety of belantamab mafodotin vs pomalidomide plus dexamethasone in relapsed/refractory multiple myeloma ( Prof Meletios Dimopoulos - National and Kapodistrian University of Athens, Athens, Greece )$

Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable...

Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA

CAR-T cell therapy targeting BCMA is highly effective for patients with...

Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Spain

$CAR-T cell therapy targeting BCMA is highly effective for patients with relapsed/refractory multiple myeloma ( Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Spain )$

Ponatinib and blinatumomab shows complete molecular response for patients with...

Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA

Ponatinib and blinatumomab shows complete molecular response for patients with Philadelphia chromosome-positive ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )

Subcutaneous isatuximab administration in combination with pomalidomide...

Prof Hang Quach - St.Vincent’s Hospital, Sydney, Australia

Subcutaneous isatuximab administration in combination with pomalidomide-dexamethasone in RRMM can improve convenience and relieve burden for patients ( Prof Hang Quach - St.Vincent’s Hospital, Sydney, Australia )

More from ecancer